Literature-reported formulation composition
Component: L829 (CICL-1) | mol%: Not reported | Role: Ionizable lipid
sales@dcchemicals.com
CICL-1 (L829)
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: Anti-CD8 targeting-moiety lipid conjugate (lipid identity not reported in supplied main article) | mol%: Not reported | Role: Targeting-lipid conjugate
Literature-reported formulation composition
Component: Three additional lipid components (identities not reported in supplied main article) | mol%: Not reported | Role: Additional lipid components
Literature-reported formulation composition
Component: Reported total | mol%: Not reported | Role: Source values retained
Reported observation
Literature-reported Peripheral B-cell depletion Sharp decline by 6 h; near-undetectable by 24 h 6 and 24 h after first IV dose · After the first CD8-L829-tLNP-CD20 dose Figure 4B and main text, Science p. 1316
Reported observation
Literature-reported CAR-positive CD8+ T cells Up to 85% After the third IV dose · Minimal CAR expression on CD4+ T cells Figure 4C and main text, Science p. 1316
Reported observation
Literature-reported CAR-positive CD8+ NK cells Up to 95% After the third IV dose · Dose-dependent expression was reported Figure 4C and main text, Science p. 1316
Reported observation
Literature-reported B-cell lineage recovery Repopulation began around day 21 and approached baseline by day 35 Recovery follow-up after 1-1.5 mg/kg dosing · Repopulating blood and tissue B cells were predominantly naïve Figure 5, Figure S12 and main text, Science p. 1316
Reported observation
Humanized-mouse leukemia study At 30 µg, four of five mice showed near-complete tumor clearance two days after the first dose, and all five did so three days after the second dose. CD8-L829-tLNP-CD19; IV 30 µg; twice weekly for five doses; human PBMC plus Nalm6 xenograft · Figure 3G and main text, Science p. 1315
Reported observation
Reduced off-target liver delivery and rapid clearance The study reported lower liver and spleen luciferase expression with untargeted L829 LNP than with the ALC-0315 benchmark, and rapid L829 clearance from mouse liver while ALC-0315 remained elevated for at least seven days. Luciferase mRNA and LC-MS studies; WT C57BL/6 mice · Figure 1B,C and main text, Science pp. 1311-1312
Reported observation
Reported tolerability and safety boundary Rat CD5-L829 tLNP was reported as tolerated up to 5 mg/kg without adverse observations, and a single 3 mg/kg IV dose was reported as safely administered in cynomolgus monkeys. In the repeat-dose anti-CD20 study, however, one monkey in the 1.5 mg/kg group developed a serious immune-effector-cell-associated event 72 h after the third dose and was euthanized. Study-specific targeted L829 tLNPs; rat and cynomolgus-monkey experiments · Figure 1D,E; main text, Science pp. 1311 and 1316